View Full Company Profile

AMERICAN SHARED HOSPITAL SERVICES

CIK: 744825 Filed: March 31, 2026 10-K

Key Highlights

  • Strategic modernization of medical fleet with high-capacity 'Esprit' technology.
  • Established market presence with 14 Gamma Knife units and global oncology support.
  • Management is actively pursuing a transition to an owner-operator model to capture higher margins.

Financial Analysis

American Shared Hospital Services: A Summary for Investors

I’ve put together this guide to help you understand how American Shared Hospital Services (ASHS) performed this year. Think of this as a "cheat sheet" to help you decide if this company fits your investment goals.

1. What does this company do?

ASHS partners with hospitals to provide high-end medical technology. Instead of a hospital spending millions to buy equipment—like Gamma Knife units for brain surgery or advanced radiation machines—ASHS buys and installs the gear. They then share the revenue generated from patient treatments. The company operates 14 Gamma Knife units and supports oncology centers across the U.S. and abroad.

2. Financial performance

The company is currently facing financial pressure. Total revenue for 2024 was $11.0 million, down from $11.5 million in 2023. Revenue from their core Gamma Knife business fell to $9.2 million. The company reported a loss of $2.8 million in 2024, compared to a $1.1 million loss in 2023. Significant capital is being directed toward upgrading to the "Esprit" technology, and current operational income is not covering equipment costs and debt obligations.

3. Major wins and challenges

  • The Win: ASHS is committed to modernizing its fleet. They have successfully upgraded several units to the "Esprit" system, which reduces treatment times and increases the capacity for hospitals to see more patients.
  • The Challenge: The company is operating with a very thin cash cushion. As of late 2024, they held only $0.6 million in cash, limiting their flexibility to handle unexpected expenses.

4. Financial health: The "Red Flag"

ASHS is currently in default on its bank loans. The company owes approximately $6.8 million. Because they missed specific financial targets, the lender, Fifth Third Bank, has restricted their ability to borrow additional funds. The bank maintains the right to demand immediate repayment of the full $6.8 million or to seize the company’s equipment. ASHS is actively negotiating with the bank to restructure these terms, but the outcome of these discussions remains uncertain.

5. Key risks

  • Bank Default: This is the most significant threat to the company. If the bank demands full repayment, ASHS lacks the liquid assets to cover the debt, which could lead to insolvency.
  • Customer Concentration: Two hospital customers account for over half of the company’s total revenue. The loss of either contract would have a severe impact on the company’s ability to generate income.
  • Debt Load: The company carries significant debt from expansion projects in Rhode Island and Mexico. High interest rates, combined with limited cash flow, make servicing this debt a primary hurdle.

6. Future outlook

Management is focused on a strategy of owning and managing their own centers to capture a larger share of profits. However, executing this strategy requires capital that the company currently lacks. Future growth is entirely dependent on resolving the current bank default and securing new funding.


Note to the reader: ASHS is in a high-stakes situation. While the company is investing in modern technology, their current financial instability and default status make this a very high-risk investment. Please weigh these risks carefully against your personal investment strategy.

Risk Factors

  • Default on $6.8 million in bank loans with Fifth Third Bank, risking asset seizure.
  • Severe customer concentration with two clients accounting for over 50% of revenue.
  • Extremely limited liquidity with only $0.6 million in cash reserves as of late 2024.
  • Inability to service debt obligations due to high interest rates and negative cash flow.

Why This Matters

Stockadora surfaced this report because ASHS is at a critical inflection point where the company's survival hinges on immediate debt restructuring. While the firm is investing in advanced 'Esprit' technology to drive future efficiency, the current default status creates a binary outcome for investors.

This report is a textbook example of high-stakes corporate turnaround efforts. Investors should watch this closely as it highlights the dangers of customer concentration and the thin margins of capital-intensive medical equipment leasing models.

Financial Metrics

Revenue (2024) $11.0 million
Net Loss (2024) $2.8 million
Cash on Hand $0.6 million
Total Debt $6.8 million
Gamma Knife Revenue $9.2 million

About This Analysis

AI-powered summary derived from the original SEC filing.

Document Information

Analysis Processed

April 1, 2026 at 05:02 PM

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.